Treatment of choice for acute severe steroid-refractory ulcerative colitis is cyclosporine

Inflammatory Bowel Diseases

Volumn 15, Issue 1, 2009, Pages 141-142

  Lichtiger, Simon ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; MEPREDNISONE; PLACEBO; STEROID; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CLINICAL TRIAL; COLON RESECTION; CONTINUOUS INFUSION; DISEASE SEVERITY; DOSE RESPONSE; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GRAND MAL EPILEPSY; HUMAN; ILEITIS; IMMUNOMODULATION; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LONG TERM CARE; MAINTENANCE THERAPY; MONOTHERAPY; NEPHROTOXICITY; PRIORITY JOURNAL; REMISSION; ULCERATIVE COLITIS; ACUTE DISEASE; DRUG RESISTANCE; REVIEW;

ACUTE DISEASE; CLINICAL TRIALS AS TOPIC; COLITIS, ULCERATIVE; CYCLOSPORINE; DRUG RESISTANCE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 61949285155     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20363     Document Type: Article

References (12)

1. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330: 1841-1845.
2. D'Haens G, Lemmens L, Geboes K, et al. Intravenous cyclosporin versus intravenous glucocorticosteroids as a single therapy for severe attacks of ulcerative colitis. Gastroenterology. 2001;120:1323-1329.
3. Svavoni F, Bonassi U, Bagnolo F, et al. Effectiveness of cyclosporine in the treatment of refractory ulcerative colitis. Gastroenterology. 1998; 114:A1096.
4. Van Assche G, D'Haens G, Noman M, et al. Randomized double-blind comparison of 4 mg/kg/day versus 2 mg/kg/day intravenous cyclosporin in severe ulcerative colitis. Gastroenterology. 2003;125:1025-1031.
5. Moskovitz D, Van Assche G, Maenhout B, et al. Incidence of colectomy during long term follow up after cyclosporin-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol. 2006;4:760-765.
6. Rolney P, Sadik R. Longer term outcome of steroid refractory ulcerative colitis treated with intravenous cyclosporine without subsequent oral cyclosporin maintenance therapy. Int J Colorectal Dis. 2002;17:67-69.
7. Naftali T, Novis B, Pomeranz I, et al. Cyclosporin for severe ulcerative colitis. Israel Med Assoc J. 2000;2:588-591.
8. Haslam N, Hearing SD, Probert CS. Audit of cyclosporin use in inflammatory bowel disease: limited benefits, numerous side effects. Eur J Gastroenterol Hepatol. 2000;12:657-660.
9. Gurudu SR, Grifell LH, Das KM. Cyclosporin therapy in inflammatory bowel disease: short and long term results. J Clin Gastroenterol. 1999; 29:151-154.
10. De Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: long term consequences and challenges for the future. Am J Kidney Dis. 2000;35:333-346.
11. Conor G, Egan L, Sandborn W. Cyclosporine, tacrolimus, and mycophenolate mofetil in the treatment of inflammatory bowel disease. Gastroenterol Clin North Am. 2004;33:141-169.
12. Cohen RD, Stein R, Hanauer SB, Intravenous cyclosporin in ulcerative colitis; a five year experience. Am J Gastroenterol. 1999;94;1587-1592.